Coherus Biosciences

Surface Oncology, Inc. is a clinical-stage immuno-oncology company focused on developing innovative cancer therapies. The company is advancing a pipeline of monoclonal antibodies, including SRF231, which inhibits CD47; NZV930, targeting CD73; SRF617, aimed at CD39; SRF388, which targets interleukin 27; and SRF813, focused on CD112R. Additionally, Surface is exploring earlier-stage programs that address critical elements of the tumor microenvironment, such as regulatory T cells and natural killer cells. The company has established collaborations with notable partners, including Novartis Institutes for Biomedical Research for cancer therapy development and Merck Sharp & Dohme Corp. to assess the safety and efficacy of combining SRF617 with KEYTRUDA, an anti-PD-1 therapy. Founded in 2014 and headquartered in Cambridge, Massachusetts, Surface Oncology aims to create conditions that enhance anti-tumor immune responses through its targeted approaches in cancer immunotherapy.

InteKrin Therapeutics is a clinical-stage, privately held biopharmaceutical company dedicated to developing innovative therapeutics for neuroendocrine, metabolic, and immune disorders. The company addresses the growing need for effective treatments for conditions such as diabetes, metabolic syndrome, and cancer, which significantly impact healthcare costs. InteKrin is actively in-licensing both early- and late-stage compounds aimed at exploring the complex hormonal interactions related to metabolism, insulin resistance, and obesity. One of its key developments includes INT131, a non-thiazolidinedione peroxisome proliferator-activated receptor gamma modulator, which targets Relapsing Remitting Multiple Sclerosis. This treatment seeks to meet the dual objectives of neuroprotection and halting the progression of this challenging disease.